menu
    • menu
    [{"orgOrder":0,"company":"Angelini Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Camphor","moa":"TRPV1","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Angelini Pharma \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Angelini Pharma"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Gaboxadol","moa":"GABA A receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Angelini Pharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Angelini Pharma \/ Angelini Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angelini Pharma \/ Angelini Pharma"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lurasidone Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Sunovion Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Sunovion Pharmaceutical"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Arvelle Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0.95999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.95999999999999996,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Angelini Pharma"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Angelini Pharma"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"JCR Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Angelini Pharma","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Angelini Pharma \/ Angelini Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Angelini Pharma \/ Angelini Pharma"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Nimesulide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Angelini Pharma \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Angelini Pharma"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Cureverse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"CV-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Angelini Pharma","amount2":0.35999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Angelini Pharma \/ Angelini Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Angelini Pharma \/ Angelini Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Angelini Pharma

    Menu

    Angelini Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CV-01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Cureverse

                            Deal Size : $360.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Angelini Pharma Signs Option Agreement with Cureverse for Brain Health Asset

                            Details : Under the agreement, Angelini Pharma will lead all the development efforts for CV-01, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases.

                            Brand Name : CV-01

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 21, 2024

                            Lead Product(s) : CV-01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Cureverse

                            Deal Size : $360.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nimesulide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Helsinn and Angelini Renew Partnership for AULIN® and MESULID® in Central Europe

                            Details : Through the agreement, Angelini Pharma will focus on commercializing Mesulid (nimesulide) in Europe. It is indicated for treating patients suffering from acute pain.

                            Brand Name : Mesulid

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 24, 2024

                            Lead Product(s) : Nimesulide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Recipient : JCR Pharmaceuticals

                            Deal Size : $505.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Angelini Pharma and JCR Pharmaceuticals Announce Global Collaboration for the Development and Commercializatio...

                            Details : The collaboration combines Angelini Pharma’s expertise in neurological diseases with JCR Pharmaceuticals’ J-Brain Cargo®, blood-brain barrier penetrating technology to develop highly innovative brain-penetrant biologic therapeutics in epilepsy.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 11, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Recipient : JCR Pharmaceuticals

                            Deal Size : $505.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : SK Biopharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France

                            Details : Cenobamate – under the brand name ONTOZRY® – has been commercialized in five major European countries such as Germany, the UK, Italy, Spain, and France, accounting for about 73 percent of the total value of the continent’s epilepsy market.

                            Brand Name : Ontozry

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2022

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : SK Biopharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cenobamate (ONTOZRY®), for the Treatment of Uncontrolled Focal-onset Seizures in Adults, Is Now Available in ...

                            Details : Ontozry (cenobamate) is a novel small molecule that provides a dual, complementary mechanism of action aimed at treatment of seizures also known as focal-onset seizures.

                            Brand Name : Ontozry

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 07, 2022

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cenobamate (ONTOZRY®), for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults, Is Now Available i...

                            Details : Pivotal trial has demonstrated that Ontozry (cenobamate) at doses of 100 mg, 200 mg, and 400 mg/day significantly improved seizure control versus placebo for adult patients with focal-onset seizures taking 1-3 ASMs.

                            Brand Name : Ontozry

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 01, 2022

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Arvelle Therapeutics

                            Deal Size : $960.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Angelini Pharma Acquires Arvelle Therapeutics

                            Details : Following Angelini Pharma’s acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom).

                            Brand Name : Xcopri

                            Molecule Type : Small molecule

                            Upfront Cash : $960.0 million

                            January 04, 2021

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Arvelle Therapeutics

                            Deal Size : $960.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lurasidone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Sunovion Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Angelini Pharma and Sunovion Pharmaceutical Europe Receive EMA Approval for Latuda for the Treatment of Adoles...

                            Details : Latuda becomes the first 2nd generation antipsychotic to be approved for patients suffering from schizophrenia as young as 13 years of age. In addition to the new indication, Latuda was also granted an additional year of marketing protection.

                            Brand Name : Latuda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 12, 2020

                            Lead Product(s) : Lurasidone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Sunovion Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gaboxadol

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Ovid Therapeutics

                            Deal Size : $232.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Comme...

                            Details : Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 for the treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, and also Switzerland, Turkey, the United Ki...

                            Brand Name : OV101

                            Molecule Type : Small molecule

                            Upfront Cash : $20.0 million

                            July 13, 2020

                            Lead Product(s) : Gaboxadol

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Ovid Therapeutics

                            Deal Size : $232.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Angelini Pharma

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Camphor,Capsicum oleoresin,Menthol

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : GSK

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Angelini Pharma Acquires ThermaCare® From GSK

                            Details : The acquired asset supports Angelini Pharma reinforcing both its Consumer Healthcare business and consolidating its International presence.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 10, 2020

                            Lead Product(s) : Camphor,Capsicum oleoresin,Menthol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : GSK

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth